{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:28:04Z","timestamp":1790692084011,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02822","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T05:16:13Z","timestamp":1543468573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein"],"prefix":"10.3389","volume":"9","author":[{"given":"Laure","family":"Yatime","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas S.","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette G.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Anton","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob A.","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubka T.","family":"Roumenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregers R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.addr.2011.06.005","article-title":"Complement in health and disease","volume":"63","author":"Carroll","year":"2011","journal-title":"Adv Drug Delivery Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.iy.04.040186.002443","article-title":"The membrane attack complex of complement","volume":"4","author":"Muller-Eberhard","year":"1986","journal-title":"Annu Rev Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0221","article-title":"The mystery behind membrane insertion: a review of the complement membrane attack complex","author":"Bayly-Jones","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol Rev."},{"key":"B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-3634-2_2","article-title":"Complement regulators and inhibitors in health and disease: a structural perspective","volume-title":"Nanomedicine","author":"Yatime","year":"2016"},{"key":"B8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4614-4118-2_10","article-title":"Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies","volume":"735","author":"Risitano","year":"2013","journal-title":"Adv Exp Med Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical hemolytic uremic syndrome depends on complement C5","volume":"22","author":"de Jorge","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B12","first-page":"3","article-title":"Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease","volume":"5","author":"Dacie","year":"1972","journal-title":"Ser Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1172\/JCI114311","article-title":"Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J Clin Invest."},{"key":"B14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","article-title":"Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"165","author":"Wong","year":"2015","journal-title":"Transl Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1681\/ASN.2010111145","article-title":"Targeting complement C5 in atypical hemolytic uremic syndrome","volume":"22","author":"Salant","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1111\/ajt.14426","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of Meningococcal Vaccine","volume":"17","author":"McNamara","year":"2017","journal-title":"Am J Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/TCRM.S96720","article-title":"Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations","volume":"12","author":"Al-Ani","year":"2016","journal-title":"Ther Clin Risk Manag."},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.molimm.2009.04.025","article-title":"Complement evasion strategies of pathogens-acquisition of inhibitors and beyond","volume":"46","author":"Blom","year":"2009","journal-title":"Mol Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.4049\/jimmunol.174.5.2926","article-title":"The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria","volume":"174","author":"Langley","year":"2005","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1073\/pnas.0910565107","article-title":"Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus","volume":"107","author":"Laursen","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jmb.2004.02.013","article-title":"Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold","volume":"337","author":"Jespers","year":"2004","journal-title":"J Mol Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/protein\/gzm037","article-title":"Repertoires of aggregation-resistant human antibody domains","volume":"20","author":"Christ","year":"2007","journal-title":"Protein Eng Des Sel."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/nprot.2007.448","article-title":"Selection of human antibody fragments by phage display","volume":"2","author":"Lee","year":"2007","journal-title":"Nat Protoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for Eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1359-0278(98)00044-3","article-title":"Proteolytic selection for protein folding using filamentous bacteriophages","volume":"3","author":"Kristensen","year":"1998","journal-title":"Fold Des."},{"key":"B31","unstructured":"Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention139 Haahr-PedersenS BjerreM FlyvbjergA MogelvangR DominquezH HansenTK 19126922J Invasive Cardiol.212009"},{"key":"B32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1681\/ASN.2013070796","article-title":"Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?","volume":"25","author":"Marinozzi","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e96910","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.4049\/jimmunol.1101749","article-title":"Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance","volume":"187","author":"Roumenina","year":"2011","journal-title":"J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1681\/ASN.2015040348","article-title":"A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H","volume":"27","author":"Chauvet","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.0706028104","article-title":"Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1","volume":"104","author":"Ramsland","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/icb.2013.28","article-title":"Full functional activity of SSL7 requires binding of both complement C5 and IgA","volume":"91","author":"Lorenz","year":"2013","journal-title":"Immunol Cell Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/emboj.2010.341","article-title":"Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex","volume":"30","author":"Laursen","year":"2011","journal-title":"EMBO J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.celrep.2012.02.003","article-title":"Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9","volume":"1","author":"Hadders","year":"2012","journal-title":"Cell Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"19642","DOI":"10.1074\/jbc.M112.361121","article-title":"Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex","volume":"287","author":"Aleshin","year":"2012","journal-title":"J Biol Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1038\/ncomms10587","article-title":"Structural basis of complement membrane attack complex formation","volume":"7","author":"Serna","year":"2016","journal-title":"Nat Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T08:19:00Z","timestamp":1573028340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2018.02822"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02822","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"article-number":"2822"}}